Metraipolis › archive › dc_c89837910a36

Pan-tumor validation of FoundationOne®CDx as a companion diagnostic for RET fusions as a predictor of response to selpercatinib — Europe PMC PMID:42211499

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42211499
DOI
10.3389/fonc.2026.1820286
License (as archived)
solo-consultazione
Archived
2026-11-02T07:25:08.818Z
SHA-256 of the archived text
5930039d62ca7853af18a676d8770ae5f34437a2d882c27187df3dc65dbf82a5
Stable URL of this page
https://metraipolis.com/documento/dc_c89837910a36

How to cite

Pan-tumor validation of FoundationOne®CDx as a companion diagnostic for RET fusions as a predictor of response to selpercatinib — Europe PMC PMID:42211499 — Europe PMC (en), https://europepmc.org/article/MED/42211499 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_c89837910a36 (Metraipolis archive dc_c89837910a36, sha256 5930039d62ca7853af18a676d8770ae5f34437a2d882c27187df3dc65dbf82a5)
BibTeX
@misc{dcc89837910a36,
  title = {Pan-tumor validation of FoundationOne®CDx as a companion diagnostic for RET fusions as a predictor of response to selpercatinib — Europe PMC PMID:42211499},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42211499},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_c89837910a36; sha256 5930039d62ca7853af18a676d8770ae5f34437a2d882c27187df3dc65dbf82a5},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42211499. Agents can read the archived copy with the MCP tool read_document.